EGFR/HER2-IN-6 (0-100 μM; 72 h) shows remarkable broad spectrum cytotoxic potency, and the cytotoxic potency against MCF7 cells is more potent than SOR [1]. EGFR/HER2-IN-6 (0-20 μM; 0-48 h) affects cell cycle and indeces apoptosis of MCF-7 cells [1]. Cell Cytotoxicity Assay [1] Cell Line: HepG2 hepatocellular carcinoma, MCF7 breast cancer, HCT-116 colorectal carcinoma, PC-3 prostate, Hea cervical epithelioid carcinoma cell lines and WI-38 fetal lung fibroblast cells Concentration: 0-100 μM Incubation Time: 72 hours Result: Exhibited cytotoxic potency to HepG2, MCF7, HCT-116, PC-3 and Hela cell lines with IC 50 s of 12.18, 2.37, 16.18, 18.39 and 9.43 μM. Showed a lower cytotoxic potency to WI-38 normal cell line with an IC 50 value of 36.84 μM. Apoptosis Analysis [1] Cell Line: MCF-7 breast cancer cell line Concentration: 0-20 μM Incubation Time: 0-48 hours Result: Through arrested cell cycle at G1/S and G1 phases and induced apoptosis in MCF-7 cells rather than necrosis to achieve anti-breast cancer activity.

EGFR/HER2-IN-6 (10 mg/kg; i.p. once per day for 20days) shows anti-breast cancer activity in mice [1]. Animal Model: 8-week-old swiss albino female mice [1] Dosage: 10 mg/kg Administration: Intraperitoneal injection; 10 mg/kg once per day; for 20 days Result: Decreased tumor volume 65.3% and reduced body weight 7.4% after 20 days of treatment.